Abstract:Botulinum toxins produced by the anaerobic bacterium Clostridium botulinum are the most potent biological toxins in nature. Traditionally, people at risk are immunized with a formaldehyde-inactivated toxin complex. Second generation vaccines are based on the recombinant carboxy-terminal heavy-chain (Hc) fragment of the neurotoxin. However, the materialization of this approach is challenging, mainly due to the high AT content of clostridial genes. Herein, we present an alternative strategy in which the native genes encoding Hc proteins of botulinum toxins A, B, and E were used to express the recombinant Hc fragments in a cell-free expression system. We used the unique property of this open system to introduce different combinations of chaperone systems, protein disulfide isomerase (PDI), and reducing/oxidizing environments directly to the expression reaction. Optimized expression conditions led to increased production of soluble Hc protein, which was successfully scaled up using a continuous exchange (CE) cell-free system. Hc proteins were produced at a concentration of more than 1 mg/ml and purified by one-step Ni(+) affinity chromatography. Mice immunized with three injections containing 5 microg of any of the in vitro-expressed, alum-absorbed, Hc vaccines generated a serum enzyme-linked immunosorbent assay (ELISA) titer of 10(5) against the native toxin complex, which enabled protection against a high-dose toxin challenge (10(3) to 10(6) mouse 50% lethal dose [MsLD(50)]). Finally, immunization with a trivalent HcA, HcB, and HcE vaccine protected mice against the corresponding trivalent 10(5) MsLD(50) toxin challenge. Our results together with the latest developments in scalability of the in vitro protein expression systems offer alternative routes for the preparation of botulinum vaccine.

Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.

Potent Tetravalent Replicon Vaccines Against Botulinum Neurotoxins Using DNA-based Semliki Forest Virus Replicon Vectors.

Enhanced Immune Responses Using Plasmid DNA Replicon Vaccine Encoding the Hc Domain of Clostridium Botulinum Neurotoxin Serotype A

Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant

Improved Immunogenicity and Protective Efficacy of A Replicon Dna Vaccine Encoding the Hc Domain of Botulinum Neurotoxin Serotype A by Electric Pulses and Protein Boosting

Pentavalent Replicon Vaccines Against Botulinum Neurotoxins and Tetanus Toxin Using DNA-based Semliki Forest Virus Replicon Vectors.

Evaluation of a Recombinant Hc of Clostridium botulinum Neurotoxin Serotype F as an Effective Subunit Vaccine

Production and Evaluation of a Recombinant Subunit Vaccine Against Botulinum Neurotoxin Serotype B Using a 293E Expression System.

Enhanced Immunogenicity to Food-And-Mouth Disease Virus in Mice Vaccination with Alphaviral Replicon-Based Dna Vaccine Expressing the Capsid Precursor Polypeptide (P1)

Vaccination with Venezuelan Equine Encephalitis Replicons Encoding Cowpox Virus Structural Proteins Protects Mice from Intranasal Cowpox Virus Challenge

Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E

Distinct Immune Responses of Recombinant Plasmid Dna Replicon Vaccines Expressing Two Types of Antigens with or Without Signal Sequences

Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system

Protection with a Recombinant Hc Ofclostridium Botulinumneurotoxin Serotype A Fromescherichia Colias an Effective Subunit Vaccine

Comparison of Immune Responses and Protective Efficacy of Suicidal DNA Vaccine and Conventional DNA Vaccine Encoding Glycoprotein C of Pseudorabies Virus in Mice

Enhanced Potency of Individual and Bivalent DNA Replicon Vaccines or Conventional DNA Vaccines by Formulation with Aluminum Phosphate

Potentiation of Anthrax Vaccines Using Protective Antigen-Expressing Viral Replicon Vectors.

Enhanced Efficacy of DNA Vaccination Against Botulinum Neurotoxin Serotype A by Co-Administration of Plasmids Encoding DC-stimulating Flt3L and MIP-3α Cytokines.

Comparative efficacy of Schistosoma japonicum bivalent DNA vaccines constructed in multimode

Experimental Study on CSFV E2 DNA Vaccine

Development and characterization of a novel neutralizing scFv vectored immunoprophylaxis against botulinum toxin type A